Making the switch — preparing for the patent expiry of the NHS's most costly biologic

With blockbuster biologic adalimumab coming off patent in October 2018, pharmacists should be ready to switch patients to the best value biologic as alternatives become available.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research